BPC-157 attenuates bowel adhesion formation in rats by promoting vascular recruitment and normalizing NO and MDA levels

Surgical procedures involving the abdominal cavity, such as parietal peritoneum excision, often lead to a serious complication: bowel adhesion formation. This process is characterized by failed vasculature at the site of injury, where tissues that are normally separate grow together. Adhesions can cause chronic pain, bowel obstruction, and infertility. Current preventative strategies are often inadequate. The stable gastric pentadecapeptide BPC-157 has shown promise in various healing contexts, particularly through its effects on blood vessels, a phenomenon termed "vascular recruitment." This study investigates whether these pro-vascular properties could mitigate the pathological processes leading to adhesions, and how it interacts with the nitric oxide (NO) system, a key signaling pathway in tissue repair and inflammation.

This was an animal study in rats with surgically induced bowel adhesions via parietal peritoneum excision. Rats were treated with BPC-157 (10 µg/kg or 10 ng/kg), L-NAME (an NO synthase inhibitor, 5 mg/kg), L-arginine (an NO precursor, 200 mg/kg), or combinations thereof. Medications were administered in three different protocols: (1) as a one-time abdominal bath during surgery; (2) via daily intraperitoneal injections for 7 or 14 days post-surgery; or (3) as a postponed therapy for pre-existing adhesions, starting on day 7. The control group received an equivolume of saline. The primary endpoints were the severity of adhesion formation and tissue levels of nitric oxide (NO) and malondialdehyde (MDA), a marker of oxidative stress.

BPC-157 treatment regimens consistently resulted in attenuated adhesions, described as "minimal or no adhesion." This beneficial outcome was associated with the rapid appearance of abundant blood vessels in and near the surgical defect. Even when administered as a postponed therapy to established adhesions, BPC-157 was effective. In contrast, nitric oxide agents had mixed effects: L-NAME worsened adhesions, while L-arginine attenuated them, and their combination counteracted each other's effects. Critically, BPC-157 maintained its positive effects when combined with L-NAME, L-arginine, or both. The study also looked at biochemical markers in the adhesion tissue.

Unlike the diverse effects of the NO-agents, BPC-157 application regularly combined a decrease in the elevated NO and MDA values with the beneficial outcome of less adhesion formation. This suggests BPC-157's mechanism involves both promoting healthy vascularization and mitigating the local inflammatory and oxidative stress environment that contributes to pathological adhesion.

Written by TitrateLab, separately from the study summarized above.